

DoD Smallpox Response Plan

INDEX

42 USC 97, 10, A-14, A-28
Accidental infection, H-11
Acronyms and Abbreviations, Appendix J-1, J-1
Active surveillance, A-10, A-12, A-15, A-37
Acute-Care Guidelines for Isolation & Infection Control, Appendix C-2, C-12
Advisory Committee on Immunization Practices (ACIP) Guidelines, Appendix J-7, J-28
Airborne precautions, F-6
Air crews, B-12
Air Force Biological Augmentation Team, D-5
Air Force Complete Immunization Tracking Application, AFCITA, B-7
Air Force Medical Logistics Office, AFMLO, I-3, I-11, I-13
Air-Handling Issues, C-6
Air Operations, 16
Ambulances, F-8
Area of Interest, 14
Atopic dermatitis, B-13, B-29, B-39, B-40
Autoclaving, F-3, I-9
Auto-Inoculation, B-4
Autopsy Specimens, D-15
Bars, B-2, B-4, B-8, B-13, B-30, B-34, D-13
Bifurcated needles, B-3, B-25
Biopsy specimen, D-11, D-13
Biosafety level, BSL, D-4, D-2
Blood Donation, B-11
Breast-feeding, E-13
Buildings, F-10
Care of the Vaccination Site, Appendix B-14, B-33
Case Classification, A-4, A-32
Case Definitions, A-1, A-4, A-32
Case Investigation Form Module, A-42
Case investigations, A-5
Case Investigations, A-5
CDC Drug Service, H-2, H-5
CDC Forms, A-6, A-12, A-15, A-17, A-19, A-42, A-43
CDC Vaccine Information Statement (VIS), B-24
Centrifugal pattern, A-30, A-31
Certainly Unexposed, 14, 19
Characteristics of Smallpox Epidemiologic Response Teams (“Smallpox Epi-Teams”),
Appendix A-4, A-23
Childhood eczema, B-39
Cidofovir, G-1, G-2, G-3, G-4, G-5, G-6, G-7, G-8, G-14, G-15, H-1, H-2, H-3, H-4, H-5,
H-6, H-8, H-18, I-1, I-2, I-3, I-5, I-6, I-7, I-9, I-11
Civil Support, B-4
Classification of Evaluated Patients, Appendix A-12, A-40

DoD Smallpox Response Plan

Cleaning, F-8, F-14, F-20
Cleaning schedule, F-10
Clinic-Flow Controllers, B-19
Clinic Vaccination Record, B-24
Clinical Care, B-9, G-2, G-10
Clinical Immunization Safety Assessment, CISA, B-3, B-5, H-3
Clinical Presentations, A-4
Close Contacts, A-5, A-12
Collection of Records, C-26
Common Questions & Answers, Appendix E-2, E-7
Communication Challenges, E-2
Communications Plans and Activities – Summary, Appendix E-1, E-6
Complication Rates After Vaccination with NYCBOH Strain of Smallpox Vaccine,
Appendix B-15, B-35
Confirmation of Take, B-10
Conjunctivitis, H-12
Consequence-Management Deployment, 12
Considerations In Air-Evacuation Of A Smallpox Patient from Overseas, Appendix J-6,
J-25
Considerations in Clinical Care of Variola Infection, Appendix G-3, G-10
Contact Identification, A-11, A-42
Contact Identification Module, A-42
Contact Identification, Tracking & Surveillance, Appendix A-13, A-41
Contact precautions, F-6, F-8, F-12, F-13
Contact Tracing, A-1, A-15, A-43
Contacts, 21, 27, C-9, C-11, C-16, C-17, C-22, C-23, C-24
Contraindications, B-2, B-6, B-8, B-12, B-13, B-15, B-16, B-18, B-19, B-24, E-13, E-18
Control, G-1, G-3, G-4, G-6, G-7, G-8
Control and Accountability, I-7
Control of Property, C-27
Cordon Sanitaire, C-29
Criteria for Type C, X, and R Facilities, Appendix C-4, C-16
Crowd Management, B-25
Cytomegalovirus, CMV, G-4
DA Form 3161, I-9, I-18
Dangerous Goods Regulations, DGR, D-4, D-18
DD Form 1348-6, DoD Single Item Requisition System Document, I-3, I-11, I-12
Decontamination & Infection Control Reference Guide, Appendix F-2, F-14
Decontamination Guidelines – Summary, Appendix F-1, F-13
Defense Eligibility Enrollment Reporting System, DEERS, B-7
Defense Logistics Agency, DLA, I-4, I-5
Defense Manpower Data Center, DMDC, B-7
Deliberate Planning & Preparedness, 12
Differential Diagnosis, A-4, A-30
Diluent, B-26
Dilutions, B-2

DoD Smallpox Response Plan

Directorate of Military Support, 13, 20
Disaster Medical Assistance Teams, DMATs, C-6
Discharge Management, F-12
Disease, E-7, E8
Disease-reporting systems, A-3, A-8, A-15, A-36
Disinfecting, F-8, F-17
Disinfecting Environmental Surfaces in Healthcare Facilities, Appendix F-4, F-17
Disposal code, I-8, I-9
Distant, 14, 27
Distribution, G-7, H-6
Distribution Operations Center, DOC, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-11, I-13, I-14, I-15, I-16
Distribution Standard System, DSS, I-4, I-5
DoD Smallpox Response Plan – Summary, Appendix 1, 19
Drug eruptions, A-31
Dryvax, B-2, B-26, B-27, I-3
Eczema vaccinatum, E-16, E-19, E-20, , H-2, H-8, H-9, H-16
Edward Jenner, E-9, E-10
Electronic Surveillance System for the Early Notification of Community Based Epidemics, A-2
Emergency, G-2, G-7
Emergency Storage, I-6
Emergency Supplies, B-25
Emergency use of an investigational drug, H-6
Endurotherm Box, I-7
Enhanced Hospital-based Surveillance, EHBS, A-10
Enhanced Hospital-Based Surveillance, Appendix A-11, A-37
Environmental Protection Agency, EPA, F-2, F-10, F-13, F-15, F-16, F-17, F-20, F-21
Environmental Surfaces., F-10
Epidemiological Investigation, A-5
Epidemiologically linked to, A-40
Epidemiology, A-15
Epi-Teams, A-4, A-5, A-8, A-9, A-11, A-13, A-23, A-24, A-26
Erythema, B-32
ESSENCE, A-2
Ethylene oxide, F-3
European Command, EUCOM, D-4
Equivocal reaction, E-21, E-22
Exceptions to General Rule to Obtain Informed Consent for Unconscious or Incapacitated Patients, Appendix G-4, G-12
Evidence from BW Sensor Alarms, ADDENDUM A, J-22
Evidence from Health Surveillance, ADDENDUM B, J-23
Expected Epidemiological Features of Smallpox, Appendix A-9, A-34
Export of Etiologic Agents, D-19
Exposure Definitions, Appendix C-6, C-22
Eye, H-9

DoD Smallpox Response Plan

Federal Bureau of Investigation, FBI, D-1, D-4, D-5, D-6
Federal Response Plan, 10, 12
Forms Collection, B-16
Forms for Contact Identification, Tracing, and Surveillance, Appendix A-14, A-42
Full-strength Dryvax, B-2
Generalized Febrile Vesicular-Pustular Rash Illness, GFVPRI, A-1, A-2, A-3, A-10, A-15, A-36
Generalized vaccinia, E-16, E-19, E-20, H-2, H-8, H-9, H-10, H-16
Generalized Vesicular or Pustular Rash Illness Protocol, A-2, A-15
Global Response, A-10
Glossary of Decontamination Terms, Appendix F-5, F-20
Glossary of Infection-Control Terms, Appendix C-13, C-39
Glycerin, B-26
Handling Instructions Of Smallpox Vaccine, Inserted Into Product Shipments, I-4, I-15
Handout to Identify Symptoms of Smallpox, Appendix A-6, A-29
Heat, ventilation and air conditioning, HVAC, C-1, C-4, C-9
Herpes zoster, A-31, A-37, A-38
High-efficiency particulate air, HEPA, C-3, C-8, C-9, C-12, C-39
Home Care Guidelines for Isolation, Appendix C-3, C-15
Home Care Guidelines for Infection Control, Appendix F-3, F-16
Hospital-approved disinfectant, HAD, C8, C-12, C-13, C-14
Host nation, A-3, A-4, A-10, A-11, A-15, A-36
Housekeeping, C-13, C-15, F-4, F-14
How to Use a Bifurcated Needle, Appendix B-12, B-31
Hyland®, H-15, H-17
Human immunodeficiency virus, HIV, G-4
Identification of Close Contacts, A-12
Immunization tracking systems, B-7, B-11
Importation of Etiologic Agents, D-18
Impromptu Training Curriculum for Contact Tracers And Interviewers, Appendix A-3, A-17
Inadvertent inoculation, H-11, H-12
Incapacitated, G-12, G-13
Incineration, I-9
IND Planning, 14
Infection Control, C-1, C-2, C-3, C-11, C-12, C-19, C-25, F-1
Infection-Control Precaution Categories, Appendix C-8, C-25
Infectious Disease Team, ID Team, D-5
Information Flow, A-36
Information Paper on Smallpox Infection and Smallpox Vaccine, Appendix 3, 21
Information Paper Describing Cidofovir, Appendix G-5, G-14
Informed Consent, B-24, G-12, G-13
Initial Symptoms of Conditions Warranting VIG Therapy, Appendix H-2, H-9
Instructions on Care of the Vaccination Site, B-24
International Air Transport Association, IATA, D-4, D-18
International Certificate of Vaccination, B-7

DoD Smallpox Response Plan

Investigational Drug Accountability, I-17
Investigational New Drugs (INDs) for Force Health Protection, Appendix B-17, B-41
Investigational new drug, IND, G-1, G-2, G-3, G-4, G-5, G-6, G-7, G-8, G-12, G-13, H-1, H-2, H-3, H-4, H-5, H-6, H-8, I-1, I-2, I-3, I-7, I-8, I-9, I-10, I-11
Isolation, C-1, C-2, C-3, C-11, C-12, C-15, C-16, C-18, C-20, C-27
Isolation and Quarantine Guidelines – Summary, Appendix C-1, C-11
Isolation Flow Charts, Appendix C-10, C-31
Isolation Procedures, Appendix C-5, C-18
Isolation of Vaccine Recipients, B-8
Issues in Quarantine, Appendix C-9, C-26
Joint Operations Center, 17
Joint Service Sensitive Equipment Decontamination, JSSED, F-10
Keratitis, H-4, H-8, H-11, H-12, H-13, H-14, H-16, H-17
Labeling, B-27, H-15, H-18
Laboratory Medical Director, D-3
Laboratory Response Network, LRN, D-1, D-4, D-5, D-6, D-7
Legal Advice, C-28
Levels in the Laboratory Response Network (LRN), Appendix D-2, D-7
Levels of Response, A-8
Linen, F-7, F-11, F-13, F-15, I-2
Local Response, A-8
Major reaction, E-21, E-22
Material Release Order, MRO, I-4, I-5
Media Impact, 17
Medical Assessment, B-16
Medical Care Of Adverse Events After Smallpox Vaccination – Summary, Appendix H-1, H-8
Medical Care Of Smallpox Patients (Variola Infection) – Summary, Appendix G-1, G-8
Medical Logistics & Product Distribution – Summary, Appendix I-1, I-11
Medical Protection System, B-7
Medical Screeners, B-18
Medical supplies, C-8
MedPROS, B-7
Management of Persons, C-27
Military Assistance to Civil Authorities, Appendix 2, 20
Military Consequence-Management Support, 12
Military Medical Support Office, B-6
Military Vaccine Office, B-6, B-10
Monitoring for Fever, A-20
Mortuary Affairs, 17
Movement Coordination Center, 17
Navy Environmental & Preventive Medicine Unit, NEPMU, D-5, D-6
Navy Forward Deployed Laboratory, D-5
Navy Medical Logistics Command, NAVMEDLOGCOM, I-3, I-9, I-11, I-13
Near, 14, 27
Negative airflow rooms, C-8

DoD Smallpox Response Plan

Neurologic reactions, 7
Noncombatant Evacuation Operations, 18
Ocular, H-2, H-8, H-9, H-11, H-12
Ocular vaccinia, H-2, H-8, H-9, H-11, H-12
Ocular Vaccinia & Ophthalmic Antiviral Medications, Appendix H-3, H-11
Operational Security, 18
Ophthalmic, H-2, H-12, H-13
Occupational Safety and Health Administration, OSHA, F-18
Orientation, B-16
Outside the Continental United States, OCONUS, B-12, G-3, G-7, H-3, I-4, I-6, I-10, I-14, I-15
Pacific Command, PACOM, D-5
Packaging, B-27
Packing and Labeling of Infectious Substances, Figure 1, D-21
Packing and Labeling of Clinical Specimens, Figure 2, D-21
Papule, B-32
Patient movement, C-10
Patient Placement, C-6, C-18, C-24
Patient Placement Considerations, Appendix C-7, C-24
Patient-Transport Vehicles, F-8
Personal Protective Equipment, PPE, C-5, C-6, C-7, C-8, C-13, C-18, C-39, F-3, F-5, F-7, F-13, F-14, F-18 I-2
Planning for Vaccine Delivery, Appendix B-2, B-14
Post-Outbreak Response, A-5
Post-Outbreak Surveillance, A-10
Posse Comitatus Act, 9
Post-mortem care, F-12, F-13
Postvaccinial encephalitis, E-16, E-17, E-19, H-16, H-17
Potentially Exposed, 14, 19
Pregnant, E-13
Prime Vendor, PV, F-7, I-2
Private Vehicles, F-9, F-16
Probably Unexposed, 14, 19
prodrome, A-29, A-31, A-40
Product Labeling for Cidofovir, Appendix H-5, H-18
Product Labeling for Vaccinia Immune Globulin (VIG), Appendix H-4, H-14
Professional Resources on Smallpox, Appendix J-3, J-10
Progressive vaccinia, E-16, E-17, E-19, E-20, H-2, H-8, H-9
Prospective Surveillance, A-37
Public Affairs, E-3, E-4, E-6
Public-Health Actions to Limit Spread of Smallpox, Appendix 5, 27
Public Health Service, PHS, B-7
Pustule, B-32
Quarantine, C-1, C-2, C-5, C-11, C-26, C-27, C-28, C-29, C-34, C-35, C-36, C-39, C-40
Quarantine Measures in Response to Smallpox Outbreak, Appendix C-11, C-33
Quarantine Regulations of the Armed Forces Pertaining to Ships, Aircraft, and Other

DoD Smallpox Response Plan

Conveyances, Appendix C-12, C-34
Rapid Response and Advanced Technology Laboratory, D-2
Rash Surveillance, A-1
Recommended Biosafety Levels for Infectious Agents, Appendix D-3, D-8
Reconstituted Vaccine, B-27
Redeployment, 12
Redistribution, I-7
Reference Publications on Smallpox, Appendix J-4, J-12
Refrigeration, I-2, I-5, I-6, I-13
Registration, B-16, B-18
Regional Response, A-9
Regulated Medical Waste, F-8, F-12, F-21, I-2
Reporting a Suspected Case, A-3
Requisitioning, I-3
Respiratory Protection Program, C-6, C-12
Response Teams, 13, 15
Response to Smallpox Vaccination, Appendix B-13, B-32
Restriction of Movement, C-11
Restriction of Movement as a Tool for the Control of Infectious Disease on the
Battlefield, Appendix J-5, J-14
Retrospective Surveillance, A-37
Safety and Security, C-6
Sample DA Form 3161, Request for Issue or Turn-In, Appendix I-6, I-18
Sample DD Form 1348-6, DoD Single Line Item Requisition System Document,
Appendix I-2, I-12
Sample Investigational Drug Accountability Record, Appendix I-5, I-17
Scab, B-32
Scab Lesions, D-13
Screening for Bars (Contraindications) to Smallpox Vaccination, Appendix B-11, B-28
Screening Sheet, B-24
Security, B-10, B-17, B-19, B-24
Select Biological Agents, D-18
Serious Incident Report, D-1
Service Reportable-Disease Surveillance Centers, Appendix A-2, A-16
Service Vaccine Control Center, I-3, I-4
Shipboard Automated Medical System, SAMS, B-7
Shipping, G-7, H-6, I-4, I-11
Ships Underway, I-9
Situation Assessment & Notification, 12
Skin Diseases Affecting Smallpox Vaccination, Appendix B-16, B-39
Smallpox Case Definitions and Case Classification, Appendix A-8, A-32
Smallpox Clinical Case Description and Differential Diagnosis, Appendix A-7, A-30
Smallpox Coordination Cell, A-3
Smallpox Coordination Cell, 14, 18, 19
Smallpox data management system, SDMS, B-7, B-12
Smallpox Vaccine Handling & Storage Instructions, Appendix B-10, B-26

DoD Smallpox Response Plan

Smallpox Vaccine Receiving and Processing Matrix, Appendix I-3, I-13
Source of Exposure Module, A-42
Special Medical Augmentation Response Teams, SMART, D-5, D-5
Specimen Collection -- Summary, Appendix D-1, D-6
Specimen Collection Procedures, Appendix D-5, D-10
Specimen Packaging, Appendix D-7, D-20
Specimen Shipping, Appendix D-6, D-17
Specimen-Collection Team, D-3
Staff Functions, B-17
Staff Training, B-20
Stages of Smallpox Infection, Appendix G-2, G-9
Standard precautions, F-6, F-15
State Health Department, A-3, A-15, A-36
State Health Laws Observed by US Officers (42 USC 97), Appendix A-5, A-28
Sterilization, F-1, F-3, F-8, F-13, F-17, F-21
Stock-record accountability, I-7
Storage, G-7, H-6
Storage requirements, B-26
Storing, I-6, I-11
Strategic Forces, 18
Summary of Specified Tasks, Appendix 4, 23
Supplies, G-7
Supply, H-6
Supplies Needed for Specimen Collection, Appendix D-4, D-9
Support to Civil Authorities, 11
Surveillance Reporting, A-36
Surveillance Reporting and Information Flow, Appendix A-10, A-36
Surveillance, Contact Tracing, & Epidemiology – Summary, Appendix A-1, A-15
Technical Escort Unit, TEU, D-5
TempTale[®], I-5, I-6, I-10, I-14, I-15, I-16
Theater Army Medical Laboratory, TAML, D-5
Threat Assessment, 6
Transition to Civilian Agencies, 12
Transport of Biomedical Materials, D-3
Treatment teams, T-Teams, G-2, G-3, G-4, G-5, G-6, G-7, G-8, H-2, H-3, H-4, H-5, H-6, H-8
Trifluridine, H-12
Tuberculocide, F-2, F-13
Type C (Contagious) Facility, C-16
Type R (Residential) Facility, C-17
Type X (Uncertain) Facility, C-16
Unconscious, G-4, G-12, G-13
Unused IND Products, I-8
Unused Non-IND Products, I-8
URLs for CDC Smallpox Response Plan Document, Appendix J-2, J-7
U.S. Army Medical Material Agency, USAMMA, I-1, I-2, I-3, I-6, I-7, I-8, I-9, I-10, I-11,

DoD Smallpox Response Plan

I-13, I-14, I-15, I-16
U.S. Army Medical Material Development Agency, USAMMDA, I-8
US Army Medical Research & Materiel Command, USAMRMC, G-2, G-5, G-6, G-8,
H-3, H-5, H-6, H-8
US Army Medical Research Institute of Infectious Diseases, USAMRIID, G-2, G-3, G-5,
G-6, G-7, G-8, H-2, H-3, H-4, H-5, H-6, H-8
Vaccination, B-1, B-6, B-7, B-10, B-12, B-13, B-16, B-17, B-18, B-20, B-22, B-23, B-24,
B-25, B-28, B-32, B-33, B-35, B-39
Vaccination Card, B-24
Vaccination Clinic Diagram, Appendix B-7, B-23
Vaccination Clinic Flow, Appendix B-6, B-22
Vaccination Clinic Process, Appendix B-3, B-16
Vaccination Clinic Staff Training, Appendix B-5, B-20
Vaccination Clinic Staffing, Appendix B-4, B-17
Vaccination Clinic Supplies & Equipment, Appendix B-9, B-25
Vaccination Documents, Appendix B-8, B-24
Vaccination Guidelines – Summary, Appendix B-1, B-13
Vaccination Referral, B-24
Vaccination-Site Care, B-7
Vaccine Adverse Event Reporting System (VAERS) Forms, Appendix B-19, B-44
Vaccine Adverse Event Reporting System, VAERS, H-5
Vaccine Delivery, B-14
Vaccine Healthcare Center, (VHC), VHC, B-3, B-5, B-6, B-10, B-43, H-3, H-8
Vaccine Healthcare Center (VHC) Services, Appendix B-18, B-43
Vaccine Recipient Diary, B-24
Vaccine Safety Surveillance, B-9
Vaccine-Vaccine Interactions, B-11
Vaccinia, I-1, I-2, I-3, I-6, I-8, I-11, I-13, I-15
Vaccinia necrosum, H-9
Varicella, A-7, A-15, A-30, , A-31, A-35, A-37, A-38
VaxiCool[®], I-6, I-7
VaxiPac[®], I-7
Vaccinia immune globulin, VIG, E-16, E-19, E-20, G-3, H-2, H-3, H-4, H-5, H-6, H-8,
H-9, H-15, H-17, I-1, I-2, I-3, I-5, I-6, I-7, I-8, I-11
Vesicle, B-32
Vidarabine, H-10
Vira-A, H-10
Viral exanthem unspecified, A-1
Viroptic, H-10
Visitors, C-13, C-15
World Health Organization, WHO, A-4, A-6, A-9, A-10
Yellow shot records, B-7